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Abstract
Introduction: Cytotoxic T-lymphocyte antigen 4 (CTLA-4) is a key negative costimulatory molecule that displays a
wide range of anti-inflammatory properties and is currently approved to treat rheumatoid arthritis as a
recombinant fusion protein (CTLA4IgG). To better understand the role of CTLA4IgG in primary Sjögren’s syndrome
(pSS), we generated a recombinant adeno-associated virus vector serotype 2 (AAV2) expressing a chimera of
mouse CTLA-4 fused with a human immunoglobulin (AAV2-CTLA4IgG) and observed the effect of this molecule in
C57BL/6.NOD-Aec1Aec2 mice, an animal model of pSS.
Methods: A recombinant adeno-associated virus-2 (AAV-2) vector was constructed encoding a CTLA4IgG fusion
protein. The AAV2-CTLA4IgG vector and an AAV2 control vector encoding beta galactosidase (LacZ) were
administered by retrograde cannulation of the submandibular glands of C57BL/6.NOD-Aec1Aec2 mice. Protein
expression was measured by ELISA and salivary glands were assessed for inflammation and activity.
Results: Recombinant CTLA4IgG blocked B7 expression on macrophages in vitro. In vivo, localized expression of
CTLA4IgG in the salivary glands of C57BL/6.NOD-Aec1Aec2 mice inhibited the loss of salivary gland activity and
decreased T and B cell infiltration as well as dendritic cells and macrophages in the glands compared with control
mice. In addition a decrease in several proinflammatory cytokines and an increase in transforming growth factor
beta-1 (TGF-b1) expression were also observed.
Conclusions: These data suggest expression of CTLA4IgG in the salivary gland can decrease the inflammation and
improve the xerostomia reported in these mice.
Keywords: Sjögren’s Syndrome, salivary gland dysfunction, adeno-associated virus (AAV), CTLA4IgG fusion protein,
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Introduction
Primary Sjögren’s syndrome (pSS) is a chronic autoim-
mune disorder that results in impaired exocrine gland
function. Xerostomia (dry mouth) and xerophthalmia
(conjunctivitis sicca, dry eyes) are hallmarks of Sjögren’s
syndrome [1]. The mechanism associated with Sjögren’s
syndrome is unclear however, immunologically-activated
or apoptotic glandular epithelial cells may present novel
autoantigens in predisposed individuals driving autoim-
mune-mediated tissue injury [2,3]. Immune activation is
typically presented as focal, mononuclear (T, B, dentri-
tic, and macrophage) cell infiltrates, proximal to the
ductal epithelial cells and forms sialadenitis [2]. Lym-
phocytic infiltrations in the salivary gland (SG) and
lachrymal glands (LG) consist of 60% to 70% CD4+ T-
lymphocytes, and a substantial numbers of B cells, den-
dritic cells (DCs), plasma, and macrophage (Mф) cells
[2,4,5]. Abnormal activation of proinflammatory Th1
[6,7], and Th17 [8] cells and cytokines such as
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interferon-g (IFN-g), interleukin-12 (IL-12), IL-17 were
reported in animal models of pSS and patient samples
[7-11]. In addition, a dramatic drop in T regulatory cells
(Treg) and decreased expression of TGF-b1 in SG infil-
trates was also reported in pSS patients [12]. Further-
more, TGF-b1 deficient mice develop a Sjögren’s
syndrome like autoimmune disease [13].
Cytotoxic T-lymphocyte antigen 4 (CTLA-4) is an
important immune regulatory protein and displays a
wide range of activities associated with immune toler-
ance. By competing with CD28 to bind B7-1/2 (CD80/
CD86), CTLA4 blocks the activation of T cells, thus
maintaining immune homeostasis [14]. CTLA-4 is con-
stitutively expressed on Treg cells and also binds to B7
on antigen-presenting cells (APCs) to inhibit activation
of effector T cells [15,16]. Recently it is noted that
epithelial cells in the minor SGs of pSS patients express
costimulatory molecules B7.1 (CD80) and B7.2 (CD86)
[17]. Correspondingly, different haplotypes of CTLA-4
were found to be associated with increased susceptibility
to pSS [18].
Currently, a recombinant fusion protein of CTLA4-
immunoglobulin (CTLA4-Ig, Abatacept, Orencia) is
licensed in the United States for the treatment of rheu-
matoid arthritis [5]. Abatacept, which contains the
CTLA-4 high-affinity binding site for B7 blocks B7:
CD28 costimulatory signaling pathway and is reported
to shut down activation of proinflammatory T cells [19]
as well as B cells, DCs, and Mф [20,21].
In order to study the affect of CTLA4 blockade on the
sialadenitis and xerostomia associated with Sjögren’s
syndrome, CTLA4IgG was locally expressed in the sali-
vary glands of C57BL/6.NOD-Aec1Aec2 mice, which
develop a Sjögren’s syndrome-like disease. Our findings
of both functional and immunological improvement in
the mice warrant further investigation of CTLA4
mediated immunomodulation as a therapeutic pathway
for treatment of pSS patients.
Materials and methods
Cell lines
HEK-293T cells were grown in Dulbecco’s modified
Eagle’s medium (DMEM). Medium was supplemented
with 10% heat-inactivated fetal bovine serum (Life Tech-
nologies, Rockville, MD, USA), 2 mM L-glutamine,
penicillin (100 U/ml), and streptomycin (100 μg/ml; Bio-
fluids, Rockville, MD, USA) as previously described [22].
Construction and testing of AAV2-CTLA4IgG
We previously reported construction of AAV2-LacZ
[23]. In this study we used the extracellular domain of
mouse Cytotoxic T-lymphocyte antigen 4 (CTLA4)
coupled to human Immunoglobulin G (IgG) Cg1
(CTLA4IgG), kindly provided by Dr Toshimitsu Uede
(Institute of Immunological Science, Hokkaido Univer-
sity, Hokkaido, Japan) [24]. This gene was cloned into
the recombinant adeno-associated virus (AAV) plasmid
containing a cytomegalovirus (CMV) promoter and the
inverted terminal repeat (ITRs) sequences for AAV sero-
type 2 (AAV2). The plasmid (AAV2-CTLA4IgG) was
transfected into HEK-293T cells and expression of the
protein in the media was determined by western blot-
ting after electrophoresis in reducing conditions using
anti-mCTLA4 Ab (R&D systems, Minneapolis, MN,
USA).
Competitive inhibition of B7 association by CTLA4IgG in
vitro
Mouse macrophages (CRL-2751, ATCC) were grown in
DMEM with 4 mM L-glutamine, 1.5 g/L sodium bicar-
bonate, 4.5 g/L glucose (Biofluids, Rockville, MD, USA),
10% fetal bovine serum, and 20% LADMAC conditioned
media (produced from the LADMAC cell line (CRL-
2420) at 37°C in a humidified, 5% CO2 atmosphere,
incubator. 1 × 105 cells/well were placed in round bot-
tom 96-well plates and spun down at 1500 rpm in a
bench top centrifuge at 4°C. The cells were then washed
twice with PBS (pH 7.4, 0.05% Tween 20) and incubated
for 1 h at 37°C with either medium from control HEK-
293T cells or from HEK-293T cells transfected with
AAV2-CTLA4IgG. Following additional washes, the
cells were incubated in the dark with 0.5 to 1 μg/ml of
Armenian hamster IgG FITC-conjugated anti B7-1
(Santa Cruz Biotechnology, Santa Cruz, CA, USA) in
blocking solution (PBS, pH 7.4, 0.5% BSA) at 4°C for 40
min. The cells were then washed and analyzed by flow
cytometry assay.
Vector production
To generate AAV2 vectors, we used the adenoviral
helper packaging plasmid pDG. Fifteen-cm plates of
approximately 40% confluent HEK-293 T cells were co-
transfected with either AAV-LacZ or AAV-CTLA4IgG
according to standardized methods [25]. Clarified cell
lysates were adjusted to a refractive index of 1.372 by
addition of CsCl, and centrifuged at 38,000 rpm for 65
h at 20°C. Equilibrium density gradients were fractio-
nated and fractions with a refractive index of 1.369 to
1.375 were collected. The particle titer was determined
by Q-PCR and the vector was stored at -80°C. On the
day of vector administration to C57BL/6.NOD-Aec1Aec2
mice, the vector was dialyzed for 3 h against saline.
Animals
Three female and ten male C57BL/6.NOD-Aec1Aec2
mice, aged six weeks, were bred and maintained at the
animal facility of the Department of Pathology, Univer-
sity of Florida, as described previously [26]. Baseline
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saliva and tear flow was collected from mice when they
were six weeks old. Gene therapy studies, as described
herein, were approved by the University of Florida’s
IACUC and IBC.
AAV2 vector administration
Mice were randomly grouped and vectors were deliv-
ered into the submandibular glands by retrograde
instillation as previously described [22] (AAV2-LaZ: 1
female, 5 males and AAV2-CTLA4IgG: 2 females, 5
males). As previously reported, the vector was well tol-
erated with no vector related inflammation [22,27].
Briefly, eight-week-old mice were mildly anesthesized
with ketamine (100 mg/ml, 1 ml/kg body weight; Fort
Dodge Animal Health, Fort Dodge, IA, USA) and xyla-
zine (20 mg/ml, 0.7 ml/kg body weight; Phoenix Scien-
tific, St Joseph, MO, USA) solution given by
intramuscular injection (IM). Ten minutes after IM
injection of atropine (0.5 mg/kg BW; Sigma, St Louis,
MO, USA), mice were administered 50 μl AAV2 vector
into both submandibular glands by retrograde ductal
instillation (1 × 1010 particles/gland) using a thin
cannula.
Detection of CTLA4IgG expression in salivary glands and
serum from C57BL/6.NOD-Aec1Aec2 mice
To confirm the stable expression of CTLA4IgG in vivo
after local delivery in the SGs from C57BL/6.NOD-
Aec1Aec2 mice, homogenates of SGs were prepared as
described previously [7]. Total protein in the superna-
tant was determined with BCA™ protein assay kit
(Pierce, Rockford, IL, USA) according to the manufac-
turer’s instructions. Blood was collected by cardiac
puncture at the time of sacrificing and collected in
microcentrifuge tubes. Serum was separated by centrifu-
gation for 20 min at 2000 g and stored at -80°C.
CTLA4IgG was detected by sandwich ELISA. A 96-
well plate (Nunc, Rochester, NY, USA) was incubated
overnight (O/N) with 0.4 μg/ml capture antibody, goat
anti-mouse CTLA-4 Ab (R&D, Minneapolis, MN,
USA) in carbonate/bicarbonate buffer (pH9.5). The
next day, wells were blocked and incubated with 100
μL of appropriately diluted standard control (0.0850
μg/ml rCTLA4, R&D, Minneapolis, MN, USA) or
serum, undiluted SG homogenates for 2 h according
to the product instructions. Following three washings,
the wells were incubated with a 1:5,000 dilution of
peroxidase conjugated affinity purified goat anti-
human IgG (Jackson ImmunoResearch, West Grove,
PA, USA) for 1 h at RT. Substrate reaction was devel-
oped following the manufacturer’s protocol and the
plate were read at OD 450 nm using a Microplate
reader model 680 (Bio-Rad Laboratories, Hercules,
CA, USA) [7].
Measurement of salivary and tear flow rates
Pilocarpine stimulated saliva flow rate (SFR) and tear
flow rate (TFR) collection was performed as described
previously [8] at the indicated time points. Briefly, indi-
vidual non-anesthetized mice were weighed and given
an i.p. injection of 100 μl of PBS containing a mixture
of isoproterenol (0.02 mg/ml) and pilocarpine (0.05 mg/
ml). Saliva was collected from the oral cavity of indivi-
dual mice for 10 min. At week 30, tear volumes from
individual animal were measured after i.p. injection of
pilocarpine (4.5 mg/g [BW]) for 20 s and determined
using a phenol red thread (Zone-Quick, FCI Ophthal-
mics, Pembrooke, MA, USA), a modified version of the
Schirmer test as described [8]. SFR and TFR were then
calculated per gram body weight.
Determination of autoantibodies
At the end of the study, serum was collected from 30-
week-old C57BL/6.NOD-Aec1Aec2 mice. An ELISA was
developed as described previously [7] to detect autoanti-
bodies against SSA/Ro [multiple antigenic peptide
(MAP)-Ro273] (University of Oklahoma Health Sciences
Molecular Biology core Facility, Oklahoma City, OK,
USA). Autoantibodies against SSB/La (total Ig) were
measured by a commercially available ELISA kit (Alpha
Diagnostic International, San Antonio, TX, USA)
according to the manufacturer’s protocol.
Histological assessment of salivary glands
Following euthanasia, whole SGs were surgically
removed from each mouse and placed in 10% phos-
phate-buffered formalin for 24 h for hematoxylin and
eosin (H&E) staining as described previously [10].
Stained sections were observed under a microscope for
glandular structure and leukocyte infiltration. Unstained
sections were used for immunofluorescence and immu-
nochemistry staining (below).
Immunofluorescence staining for CD3+T cells and B220+B
cells
Immunofluorescence staining for T and B cells for the
infiltrations in the SGs was done as previously described
[8]. Briefly histological sections of salivary glands were
incubated with rat anti-mouse B220 (BD Pharmingen,
San Jose, CA, USA) and goat anti-mouse CD3 (Santa
Cruz Biotechnology, Santa Cruz, CA, USA), followed by
incubation with Texas Red-conjugated rabbit anti-rat
IgG (Biomeda, Foster City, CA, USA) and FITC-conju-
gated rabbit anti-goat IgG (Sigma-Aldrich, St. Louis,
MO, USA). The slides were mounted with DAPI-
mounting medium (Vector Laboratories, Burlingame,
CA, USA). Sections were observed at 200× magnifica-
tion using a Zeiss Axiovert 200M microscope, and
images were obtained with AxioVs40 software (Ver.
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4.7.1.0, Zeiss) (Carl Zeiss, Thornwood). The number of
lymphocytic foci (LF) in each section was blindly enum-
erated by three individual investigators. The number of
B and T cells, and total number of nuclei in each LF
were determined using Mayachitra image software
(Mayachitra, Inc., Santa Barbara, CA, USA).
Immunohistochemical staining for CD11c and F4/80 in
salivary glands
Paraffin-embedded SGs were deparaffinized by immer-
sion in xylene, followed by antigen retrieval with 10 mM
citrate buffer, pH 6.0. Tissue sections were then incu-
bated overnight at 4°C with anti-CD11c or anti-F4/80
antibody (Santa Cruz Biotechnology Santa Cruz, CA,
USA). Total rabbit IgG was used as an isotype control.
The slides were incubated with biotinylated goat anti-
rabbit IgG secondary antibody followed by horseradish
peroxidase-conjugated strepavidin incubation using the
Vectastain ABC kit. The staining was developed by
using diaminobenzidine substrate (Vector Laboratories,
Burlingame, CA, USA), and counterstaining was per-
formed with hematoxylin. Sections were photographed
at 200× magnification using a Zeiss Axiovert 200M
microscope, and images were obtained with AxioVs40
software (Ver. 4.7.1.0, Zeiss) (Carl Zeiss, Thornwood).
The number of CD11c or F4/80-positive cells was
counted by three different examiners and the mean of
three counting were determined.
Detection of cytokines from immune cell cultures and SG
homogenates
Cytokines from spleen cell and draining lymph nodes
(DLN) cell culture, serum, and homogenates of SGs
were detected as described previously [28]. Briefly cells
from spleen and submadibular salivary gland (SMGs)
associated DLNs obtained from treated mice were iso-
lated respectively and samples from mice in each group
were pooled and cultured in 24-well plates at 5 × 106
cells/ml RPMI-1640 medium (Invitrogen, Carlsbad, CA,
USA), containing HL-1 serum replacement (Cambrex
Bioscience, Walkersville, MD, USA), with or without 1
μg/ml Concanavalin A (ConA, Sigma-Aldrich, St Louis,
MO, USA). Supernatants were collected after 48 h incu-
bation. Serum and SMG homogenates were prepared as
described previously [7,28] and three samples from
representative mice in each group were used for
detection.
Murine interleukin-6 (IL-6), tumor necrosis factor-a
(TNF-a), IL-12 p70, interferon-g (IFN-g), IL-18, IL-17,
IL-23, transforming growth factor-b1 (TGF-b1), mast
cell proteinase-1 (MCP-1), and macrophage inflamma-
tory proteins-1 (MIP-1) were measured using a multi-
plex sandwich-ELISA assay (Aushon Biosystem Billerica,
MA, USA). Duplicates for each sample were tested in
three dilutions and the mean values of the duplicates
from the optimal dilution were reported [28].
Statistical analysis
Mann-Whitney U test was used to analyze differences of
cytokine production in serum. Unpaired student t-test
was used to analyze differences between two experimen-
tal groups in other assays. All analyses were performed
with GraphPad Prism statistical software (GraphPad
Software Inc. version 4.02, La Jolla, CA, USA) using a P
value ≤0.05 as statistically significant.
Results
Detection of CTLA4IgG and binding to B7 in vitro
Prior to analyzing stable expression of CTLA4IgG from
AAV2-CTLA4IgG in the SGs of C57BL/6.NOD-
Aec1Aec2 mice, we confirmed both the expression and
the biological activity of the fusion protein by western
blot, and by blocking the B7:CD28 pathway in vitro,
respectively.
Fusion of the Cg1 domain of IgG to the binding
domain of CTLA4 resulted in a chimeric protein of
approximately 62 kDa. Secretion was confirmed by wes-
tern blot of the cell culture media from transfected cells
(Figure 1A).
Macrophages, like dendritic cells, are one of the anti-
gen presenting cells (APCs) that express the costimula-
tory molecule B7. To test the ability of the recombinant
CTLA4IgG to bind and block B7 detection, supernatant
from CTLA4IgG expressing cells was preincubated with
macrophages and then B7 quantified by flow cytometry
assay. Compared to macrophages incubated without
CTLA4IgG, unbound and detectable B7 expression on
the macrophages incubated with CTLA4IgG was
decreased, suggesting binding between B7 and
CTLA4IgG.
In vivo expression of CTLA4IgG following cannulation
with AAV2-CTLA4IgG in C57BL/6.NOD-Aec1Aec2 mice
Salivary gland infiltrating lymphocytes in C57BL/6.
NOD-Aec1Aec2 are first detected between 8 and 12
weeks of age. However, microarray analysis indicates
that adhesion molecules as well as genes associated with
macrophages and dendritic cells are upregulation as
early as 8 weeks of age. Prior to 8 weeks SGs are not
considered fully mature. Thus, we chose to cannulate
the glands at 8 weeks which would be considered an
our early stage of disease [29]. As previously reported,
cannulation of these mice with AAV vectors was well
tolerated and no vector related inflammation was
observed [22,27]. To confirm the stable expression of
CTLA4IgG in vivo after local delivery of AAV2-
CTLA4IgG to the SGs of C57BL/6.NOD-Aec1Aec2
mice, SG homogenates and serum were obtained at the
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end of the study (30 weeks) and pooled according to
each group. Using a sandwich-ELISA to detect the
recombinant chimeric protein (mouse CTLA4 and
human IgG), mice that received AAV2-CTLA4IgG had
much higher levels of CTLA4IgG (44.5 ± 0.76 pg/ml in
SG and 7.48 ± 0.70 pg/ml in serum, mean ± SD) in
both their SG and serum compared with mice that
received vector expressing LacZ (0.39 ± 0.02 pg/ml in
SG and 0.62 ± 0.01 pg/ml in serum) (P = 0.0003 and P
= 0.0102, respectively, in SG and serum) (Figure 2). In
agreement with the local delivery of vector, the level of
expression in the SG homogenates was elevated com-
pared with serum in the AAV2- CTLA4IgG-treated
mice.
Local expression of AAV2-CTLA4IgG prevents the age-
dependent loss of salivary gland activity in C57BL/6.NOD-
Aec1Aec2 mice
To better understand the effect of CTLA4IgG on SG
function, stimulated saliva flow was measured in both
treated and control mice over time. In agreement with
previous studies [26], mice treated with the control
LacZ expressing vector showed a significant decrease of
saliva flow by 16 weeks (4.25 ± 0.64 μL/g 10 min), com-
pared with the baseline flow at 6 weeks (6.10 ± 0.30 μL/
g 10 min), which continued to decline over time [8].
Mice that received AAV2CTLA4IgG vector initially also
showed some decrease in saliva flow at 16 weeks (5.13 ±
1.22 μL/g 10 min), but it was not statistically significant
compared with the 6-week baseline (P = 0.2057). How-
ever, by 22 weeks the saliva flow from the CTLA4IgG
mice had recovered to near baseline values (6.13 ± 0.92
μL/g 10 min), which was sustained for the remainder of
the study, and was statistically different compared with
the AAV2-LacZ-treated group at 30 weeks (P = 0.0222).
These data suggest that expression of CTLA4IgG in the
SGs of C57BL/6.NOD-Aec1Aec2 mice can inhibit the
loss of SG function (Figure 3A).
Salivary gland transduction with AAV2 CTLA4IgG had
only minimal affect on lachrymal gland dysfunction in
C57BL/6.NOD-Aec1Aec2 mice
Previous research has suggested that following cannula-
tion of the SG, greater than 90% of the AAV2 vector
remains in the gland [27]. Similarly higher levels of the
expression can also be detected locally in the gland
homogenates compared with circulating levels. In order
to test if the circulating levels of CTLA4IgG were suffi-
cient to have an effect on other secretory epithelia such
as the loss of lachrymal gland function in the C57BL/6.
Figure 1 In vitro expression and activity of CTLA4IgG. (A) In vitro expression of CTLA4IgG was detected by western blot of media from
AAV2-CTLA4 transfected cells (lane 3). As a control, purified recombinant mouse CTLA4/Fc was also run on the gel (lane 2). (B) Biological activity
of CTLA4IgG, based on its ability to bind and block B7.1, was determined by incubating with either medium from naïve HEK-293T cells (column
1) or from cells transfected with AAV2CTLA4 (column 2). Unbound B7.1 was then tested by flow cytometry using an antibody to B7.1. Data
shown is mean from three independent experiments (asterisk, P = 0.0400). Unpaired student-t test was used in this analysis.
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NOD-Aec1Aec2 mice, we measured stimulated tear flow
at the end of the study. CTLA4IgG-treated mice had an
overall increase in tear flow compared with the LacZ-
expressing group, but was not significantly different (P
= 0.1316) (Figure 3B).
CTLA4IgG expression does not change autoantibody
levels in C57BL/6.NOD-Aec1Aec2 mice
To observe the effect of CTLA4IgG on the regulation of
systemic B cell activation, we measured anti-Ro (SSA)
and anti-La (SSB) autoantibodies, which are highly
Figure 2 In vivo expression of CTLA4IgG in salivary glands from C57BL/6.NOD-Aec1Aec2 mice. A sandwich ELISA was developed to detect
expression of mouse CTLA4 and human IgG (CTLA4IgG) chimeras in homogenates of submandibular salivary glands (A) and serum (B) (Materials
& Methods). Data show the mean ± SEM from each group. Mice cannnulated with AAV2-CTLA4IgG (n = 6, pooled into two samples/group) had
significant levels of CTLA4IgG protein in the salivary glands compared with mice that received AAV2-LacZ (n = 7, pooled into two samples/
group), (two asterisks, P = 0.0003) and serum (asterisk, P = 0.0102) Unpaired student-t test was used in this analysis.
Figure 3 Stimulated saliva and tear flow in treated C57BL/6.NOD-Aec1Aec2 mice. Saliva and tear flow were collected as described in the
Materials & Methods section. The data shown represent the mean ± SEM flow per group (n = 6 in AAV2-LacZ group and n = 7 in AAV2-
CTLA4IgG group). Unpaired student t-test was used in this analysis. (A) Mice treated with vector expressing CTLA4IgG showed protection from
loss of gland activity. Saliva was collected over a 10-min period after stimulation with a 100 μl of PBS containing a mixture of isoproterenol (0.02
mg/ml) and pilocarpine (0.05 mg/ml) and tear flow were collected over a 20-s period after injection of pilocarpine (4.5mg/kg body weight).
AAV2-LacZ mice showed decreased saliva on weeks 16, 22, 26, and 30 (asterisk, P = 0.0428, 0.0217, 0.0292, and 0.0128, respectively), compared
with the baseline saliva collection on week 6 (n = 9, 5.933 ± 0.2969). AAV2-CTLA4IgG-treated mice had a slight decrease of saliva but this was
not significant at 16 weeks (P = 0.2057). Saliva flow of CTLA4IgG-treated mice increased to baseline level by 22 weeks (6.13 ± 0.92 μL/g 10 min).
CTLA4IgG-treated mice had increased saliva flow compared with LacZ-treated mice by 30 weeks (P = 0.0232). (B) Delivery of AAV2-CTLA4IgG
resulted in an increase in tear flow (mean ± SEM) by 30 weeks compared with control mice, but this was not significant (P = 0.1316).
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correlated with pSS [30]. Minimal changes in anti-Ro
and anti-La titer were detected in the CLTA4IgG-trea-
ted mice compared with the AAV2-LacZ-treated mice
(Figures 4A and 4B).
Salivary gland transduction with AAV2 CTLA4IgG can
decrease infiltrating T and B cells, DCs, and Mф
To determine the effect of CTLA4IgG on lymphocyte
foci (LF) in the SGs, we detected the number of LF as
well as the number of T and B cells within the gland
by immunofluorescence staining of CD3 and B220,
respectively (Figures 5A, B, C, and 5D). The number of
LF were decreased in the SGs of CTLA4IgG mice (0.71
LF/per gland) compared with control LacZ mice (2.16
LFs/per gland). Furthermore, the number of T and B
cells present in the LF also decreased. Although the
decrease in T cells was significant, the change in B
cells was not statistically significant compared with
control LacZ-treated mice (P = 0.0464 and P = 0.3024
for analysis of T and B cells, respectively) (Figures 5C,
D, E and 5F).
An increase in DCs and macrophages has also been
reported in the SGs of pSS patients [31]. The number
of DCs and Mф cells (detected by staining for CD11c+
DCs and F4/80+, respectively) was significantly
decreased in the CTLA4IgG-treated group compared
with the LacZ control group (DCs: 13.33 ± 2.78/gland
in LacZ group vs. 2.14 ± 0.70/per gland in CTLA4IgG
mice, P ≤0.01. Mф: 14.89 ± 0.11/gland in LacZ group
vs. 3.84 ± 2.31/per gland in CTLA4IgG mice, P
≤0.0001) (Figure 5E, F, G, H, I, J, K and 5L). These
data indicate that local expression of CTLA4IgG can
inhibit T-cell accumulation in the SG, as well as DCs
and Mф.
CTLA4IgG expression decreased proinflammtory cytokines
and increased TGF-b1 in salivary gland associated lymph
nodes
To investigate cytokine production after CTLA4IgG
expression, we measured the levels of cytokine asso-
ciated with different populations of T cells or macro-
phages in both spleen and serum as well as locally in
the SG and associated draining lymph nodes (DLN).
In SG homogenates, only a decrease in IL-6 was
observed in the AAV2-CTLA4IgG-treated mice (median
= 169.60 pg/ml) compared with AAV2-LacZ controls
(median = 86.51 pg/ml), which was not statistically sig-
nificant (P = 0.9062, data not shown). Interestingly,
TGF-b1 production increased in the CTLA4IgG group
compared with control LacZ-treated mice, however the
increase was not statistically significant (median =
1208.70 pg/ml vs. median = 804.53 pg/ml, respectively)
(P = 0.093, data not shown). In the pooled cell culture
media of the DLN cells associated with the SG, a gen-
eral down-regulation in proinflammatory cytokine was
observed in the CTLA-4IgG-treated mice compared
with control LacZ mice. Th1 cytokines (IL-12, IFN-g,
and IL-18) and Th17 cytokine (IL-23) were all down-
regulated. Again, TGF-b1 was strikingly up-regulated. In
addition, non-specific proinflammatory cytokines, IL-6
and TNF-a, as well as chemokines MCP-1 and MIP-1a,
which are mainly released from macrophages, were
decreased (Table 1). Little change was detected in Th2
cytokines such as IL-4, IL-5, and IL-13 after local
expression of CTLA4IgG (data not shown). These
changes suggest that CTLA4IgG expression can reduce
proinflammatory cytokines released by Th1, Th17 cells,
DCs, and macrophages, while stimulating production of
anti-inflammatory cytokines such as TGF-b1. This
Figure 4 Serum anti-nuclear antibody productions in C57BL/6.NOD-Aec1Aec2 mice. Serum samples were analyzed for anti-Ro (SSA) (A) and
anti-La (SSB) (B) antibody expression in serum from AAV2-LacZ (n = 6) and AAV2-CTLA4IgG (n = 7) treated mice by ELISA. The data shown
represent the mean ± SEM in OD or U/ml from duplicate tests of pooled samples from each group. Unpaired student’s t-test was used for
statistical analysis. No statistically significant difference was detected (P = 0.9586 and 0.4158, respectively).
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Figure 5 Histological examination of salivary glands. Salivary gland histology was examined at the end of the study (30 weeks of age). CD3
+T and B220+B cell immunofluorescence staining, as well as CD11c and F4/80 immunochemistry staining for dendritic and macrophages cells
respectively were done as described in Materials and Methods. Panels show representative immuno-fluorescence staining of salivary of B and T
cells in SGs from mice cannulated with AAV2-LacZ (n = 6) or AAV2-CTLA4IgG vector (n = 7) (A, B, and C) (Blue arrows) and enumeration (mean
± SEM) (D) of B and T cells in SGs from LacZ- and CTLA4IgG- treated mice; immunohistochemical staining and enumeration (mean ± SEM) of
CD11c+ DCs (E, F, G, and H) and F4/80+ macrophages (I, J, K, and L) (Black arrows) in SGs from LacZ- and CTLA4IgG-treated C57BL/6.NOD-
Aec1Aec2 mice. A statistical decrease in the enumeration of both T cells was shown in the SGs from CTLA4 overexpressing mice compared to
the LacZ-treated (P = 0.0464). No statistical significance but a trend was shown (P = 0.3024) for decrease trend of B cells. Significant down-
regulation of both CD11c+ dendritic cells and F4/80+macrophages was seen in the SGs from CTLA4IgG-treated mice compared with control
(two asterisks, P ≤0.01). Unpaired student-t test was used in the analysis.
Table 1 Cytokine production local and systemic immune system in vector treated mice (pg/ml)
DLN cells Spleen cells Serum
LacZ CTLA4IgG LacZ CTLA4IgG LacZ CTLA4IgG
Th1- IL-12p70 12 0.00↓ 4.6 0.20 88.5 ± 15.8 88.5 ± 15.8
IFN-g 3.8 0.00↓ 122 115.0 872.6 ± 1,276.8 457.2 ± 371.8↓
IL-18 11 0.00↓ 16 0.00↓ 694 ± 562 394.10↓
Th17- IL-17 N/A N/A 2.1 0.00↓ 2.8 ± 3.3 N/A↓
IL-23 14 N/A↓ 78.2 36.10↓ 335.6 ± 365.7 101.99↓
Treg- or SG epithelial cells TGF-b1 N/A 41,410↑ 2,084 1,384 1,501,176 ± 277,249 1,260,620 ± 289,478
Non-specific (Macrophages) IL-6 2452 1,688↓ 2,557 2,407 309 ± 1,241 289 ± 355
TNF-a 43 27↓ 98 120 37 ± 83 41 ± 142
Chemokines MCP-1 10 2↓ 44 43 63 ± 19 66 ± 26
MIP-1a 224 130↓ 357 237 2 ± 0.2 2.5 ± 2.5
Serum, splenocytes, and salivary gland DLNs were collected at the end of the study. Splenocytes and DLN cells were pooled according to vector treatment
group. Culture supernatants were collected following incubation with or without ConA for 48 h. Cultures and serum were then analyzed for levels of the
indicated cytokines (in pg/ml) by multi-cytokine assay in duplicate. For cell cultures, values are the mean of duplicate tests of ConA treated cells subtracted from
media alone. For serum, the data shown were the median ± SD of each group of mice (AAV2-LacZ [n = 6] and AAV2-CTLA4IgG [n = 7], respectively]. Mann-
Whitney U test was used to analyze differences of cytokine production in serum. ↑: Production of cytokines in the AAV2-CTLA4IgG group is ≥ 50% higher than in
AAV2-LacZ group; ↓: Production of cytokines in the AAV2-CTLA4IgG group is ≥ 50% lower than the AAV2-LacZ group.
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further supports the finding of reduced inflammation
with CTLA4IgG treatment.
Effect of CTLA4IgG on regulation of systemic T cell
response in the C57BL/6.NOD-Aec1Aec2 mice
To test for changes in the systemic immune system,
cytokines were also measured in serum and in spleen
cell cultures. Wide variation was seen in cytokine values
in serum, and none of the cytokine levels from the
CTLA4IgG and LacZ groups showed statistical signifi-
cance. However, a decrease (a change in the median of
≥ 50%) in a majority of cytokines associated with Th1
and Th17 cells, such as IFN-g, IL-18, IL-17, and IL-23,
was seen in the serum of AAV2-CTLA4IgG-treated
mice compared with AAV2-LacZ-treated mice. In addi-
tion, production of IL-12, IL-18, IL-17, and IL-23 from
splenocytes was down-regulated in the AAV2-
CTLA4IgG-treated group compared with the AAV2-
LacZ-treated mice. Unlike the local immune response
seen in the SG associated DLN, minimal change in non-
specific cytokines, chemokines, or TGF-b1 was detected
in serum or cultured splenocytes. These data imply that
CTLA4IgG expression can also decrease proinflamma-
tory cytokines in the peripheral immune system, follow-
ing local SG gene transfer in C57BL/6.NOD-Aec1Aec2
mice (Table 1).
Discussion
The blockade of CD28 co-stimulation by recombinant
CTLA4IgG (abatacept) has demonstrated clinical utility
in the treatment of rheumatoid arthritis [14]. In our
study, local expression of CTLA4IgG by gene transfer to
the SGs of C57BL/6.NOD-Aec1Aec2 mice, a pSS animal
model, resulted in a decrease in the sialoadenitis and
improvement in gland function compared with mice
that received a control vector.
The advantage of localized gene transfer is to direct
the expression of the therapeutic molecule to the site of
maximum effect while minimizing the systemic compli-
cations that can be associated with off target effects.
Using this approach we were able to achieve much
higher local concentrations of CTLA4IgG in the salivary
glands compared to circulating levels in the serum. Our
data further confirm that ductal cells within the gland
represent a good depot site for production of recombi-
nant proteins [32]. Indeed, previous experiments have
demonstrated expression from salivary gland ductal cells
for the life of the animal [33].
In both patients and C57BL/6.NOD-Aec1Aec2 mice,
activated CD4+ T lymphocytes including Th1 and Th17
cells infiltrate the salivary and lachrymal glands, and
produce a variety of proinflammatory cytokines, such as
IFN-g and IL-17, which may trigger gland damage and
represent a crucial element in the pathogenesis of pSS
[2,34]. Although not statistically significant, we did
detect a decrease in Th17 cytokine in both the DLN
and spleen following expression of CTLA4IgG, suggest-
ing a corrective shift in this critical cell population.
Besides the negative effect on T cells as a result of
blockade of the B7:CD28 costimulatory pathway [19], it
is also noted that recombinant CTLA4IgG may directly
or indirectly deactivate DCs, macrophages and B lym-
phocytes [15,21]. Our data indicate that in C57BL/6.
NOD-Aec1Aec2 mice, CTLA4IgG expression results in a
decrease in T and B lymphocytes as well as DCs and
macrophages in the SG that is accompanied by a down-
regulation in proinflammatory cytokines. Our finding is
in agreement with previous reports on the effect of
CTLA4IgG in other autoimmue disease model [20,21].
Interestingly, a significant increase in TGF-b1 expres-
sion in both the SG and the DLNs was observed. The
increase in TGF-b1 expression maybe related to an
increase in nTreg or negative regulation of epithelial
cells by CTLA4IgG [15]. In addition to its role in the
immune system, TGF-b1 expression was found to be
important in maintaining epithelial tight junctions, an
important component in the fluid movement of SGs
[35] and therefore may be directly related to the
improvement in saliva flow.
Our study suggests an improvement of SG function,
which could result from the inhibition of sialadenitis
after local expression of CTLA4IgG. This suggests that
local delivery of AAV2-CTLA4IgG is a promising treat-
ment of pSS. In addition, some improvement in lachry-
mal gland was also observed. This difference is likely
related to the lower circulating levels of CTLA4IgG in
the serum compared with the levels in the salivary gland.
Despite the positive results achieved in this study, the cir-
culating levels of CTLA4IgG are well below those clini-
cally used with abatacept (http://packageinserts.bms.
com/pi/pi_orencia.pdf). Further increases in the dose of
vector or the use of vectors with improved gene transfer
activity in the salivary gland are likely to result in higher
circulating levels and may have a more significant impact
on extraglandular manifestations of Sjögren’s syndrome.
Gene therapy is still considered an experimental pro-
cedure. However, to date more than 200 clinical trials
have been conducted and recently many are showing
promising results in treating hemophilia, cancer, immu-
nodeficiencies, and blindness. An ongoing trial targeting
the salivary glands is also reporting positive results sug-
gesting that gene transfer to the salivary gland is possi-
ble [36]. In summary, our data suggest that inhibition of
the costimulatory pathway CD28 by expression of
CTLA4IgG locally in the salivary gland can be a useful
approach for reducing the inflammation and improving
the secretory activity associated with Sjögren’s
syndrome.
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Conclusions
Our data suggest expression of CTLA4IgG can reduce
the sialadenitis and improve secretory activity in a
mouse model of pSS. In addition to identifying a novel
intervention in pSS, our findings support the importance
of co-stimulatory pathways as a therapeutic target of the
disease.
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